Updating results

477 results

Sort: Relevance | Date

Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

In development [GID-TA10589] Expected publication date: TBC

Technology appraisal guidance In development

MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

In development [GID-TA10573] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) ID1585

In development [GID-TA10538] Expected publication date: 12 August 2020

Technology appraisal guidance In development

Nivolumab with cisplatin and fluorouracil for untreated advanced oesophageal squamous cell carcinoma [ID2712]

In development [GID-TA10572] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

In development [GID-TA10512] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]

In development [GID-TA10581] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683

In development [GID-TA10537] Expected publication date: 12 August 2020

Technology appraisal guidance In development

Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

In development [GID-TA10583] Expected publication date: TBC

Technology appraisal guidance In development

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

In development [GID-TA10467] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]

In development [GID-TA10571] Expected publication date: 25 August 2021

Technology appraisal guidance In development

Atezolizumab with paclitaxel for untreated unresectable advanced triple-negative breast cancer [ID2705]

In development [GID-TA10570] Expected publication date: TBC

Technology appraisal guidance In development

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

In development [GID-TA10569] Expected publication date: TBC

Technology appraisal guidance In development

Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 3 therapies [ID2701]

In development [GID-TA10568] Expected publication date: TBC

Technology appraisal guidance In development

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]

In development [GID-TA10582] Expected publication date: TBC

Technology appraisal guidance In development

Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]

In development [GID-TA10580] Expected publication date: TBC

Technology appraisal guidance In development

Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]

In development [GID-TA10579] Expected publication date: 21 April 0201

Technology appraisal guidance In development

Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]

In development [GID-TA10578] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]

In development [GID-TA10576] Expected publication date: TBC

Technology appraisal guidance In development

Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

In development [GID-TA10575] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab in combination for untreated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID2700]

In development [GID-TA10574] Expected publication date: TBC

Technology appraisal guidance In development

Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Highly specialised technologies guidance In development

Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Highly specialised technologies guidance In development

Implantable Vagus Nerve Stimulator in Heart Failure

In development [GID-IP1145] Expected publication date: TBC

Interventional procedures guidance In development

Ex utero intrapartum therapy for fetal obstruction

In development [GID-IP1156] Expected publication date: TBC

Interventional procedures guidance In development

Peroral endoscopic myotomy (POEM) for achalasia

In development [GID-IP1229] Expected publication date: TBC

Interventional procedures guidance In development

Extra corporeal membrane oxygenation for acute heart failure in children

In development [GID-IP1153] Expected publication date: TBC

Interventional procedures guidance In development

Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children

In development [GID-IP1170] Expected publication date: TBC

Interventional procedures guidance In development

Cutting blocks for total knee arthroplasty

In development [GID-IP1112] Expected publication date: TBC

Interventional procedures guidance In development

Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

In development [GID-IP1151] Expected publication date: TBC

Interventional procedures guidance In development

Intravaginal sling for stress urinary incontinence

In development [GID-IP267] Expected publication date: TBC

Interventional procedures guidance In development

Degradable surgical implant

In development [GID-IP1197] Expected publication date: TBC

Interventional procedures guidance In development

MRI guided focussed ultrasound for chronic pain

In development [GID-IP1043] Expected publication date: TBC

Interventional procedures guidance In development

Electrochemotherapy for the treatment of malignant melanoma

In development [GID-IP1041] Expected publication date: TBC

Interventional procedures guidance In development

Juvenile idiopathic arthritis - adalimumab [ID385]

In development [GID-TAG400] Expected publication date: TBC

Technology appraisal guidance In development

Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

In development [GID-TAG385] Expected publication date: TBC

Technology appraisal guidance In development

Clinically isolated syndrome - beta interferons and glatiramer acetate [ID109]

In development [GID-TAG415] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - idraparinux sodium [ID375]

In development [GID-TAG383] Expected publication date: TBC

Technology appraisal guidance In development

Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]

In development [GID-TA10121] Expected publication date: TBC

Technology appraisal guidance In development

Heart failure (acute decompensated) - nesiritide [ID384]

In development [GID-TAG376] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]

In development [GID-TAG391] Expected publication date: TBC

Technology appraisal guidance In development

Diabetic retinopathy - ruboxistaurin [ID382]

In development [GID-TAG386] Expected publication date: TBC

Technology appraisal guidance In development

Binimetinib for treating melanoma [ID833]

In development [GID-TA10074] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]

In development [GID-TA10028] Expected publication date: TBC

Technology appraisal guidance In development

Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

In development [GID-TA10033] Expected publication date: TBC

Technology appraisal guidance In development

Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]

In development [GID-TAG431] Expected publication date: TBC

Technology appraisal guidance In development

Falls - faller's clinics [ID103]

In development [GID-TAG375] Expected publication date: TBC

Technology appraisal guidance In development

Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

In development [GID-TAG414] Expected publication date: TBC

Technology appraisal guidance In development

Prostate cancer (prevention) - dutasteride [ID75]

In development [GID-TAG409] Expected publication date: TBC

Technology appraisal guidance In development

Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

In development [GID-TAG411] Expected publication date: TBC

Technology appraisal guidance In development

Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]

In development [GID-TAG337] Expected publication date: TBC

Technology appraisal guidance In development